State-of-the-Art PaperResponse Variability to P2Y12 Receptor Inhibitors: Expectations and Reality
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Siller-Matula has received lecture or consultant fees from AstraZeneca, Daiichi Sankyo, and Eli Lilly and Company; and a research grant from Roche. Prof. Trenk has received consultant fees or advisory board fees from Eli Lilly and Company, Daiichi Sankyo, and AstraZeneca; and lecture fees from Eli Lilly and Company Daiichi Sankyo, AstraZeneca, Boehringer Ingelheim KG, and Bayer. Prof. Schrör has received lecture or consultant fees from AstraZeneca, Bayer, Eli Lilly and Company/Daiichi Sankyo, and Iroko Pharmaceuticals; and is on the advisory boards of Eli Lilly and Company and Bayer. Prof. Gawaz has received lecture fees from AstraZeneca, Bayer Vital, Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly and Company. Prof. Kristensen has received lecture fees from AstraZeneca, Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Iroko Pharmaceuticals, Merck & Co., Pfizer, Sanofi, and The Medicines Company. Prof. Storey has received honoraria, consultanct fees, and/or institutional grants from AstraZeneca, Merck & Co., Accumetrics, Eli Lilly and Company/Daiichi Sankyo, sanofi-aventis/Regeneron, Bristol-Myers Squibb, Iroko Pharmaceuticals, Medscape, Eisai, Novartis, and Roche. Prof. Huber has received lecture and consultant fees from AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, sanofi-aventis, Bristol-Myers Squibb, Pfizer, Iroko Pharmaceuticals, and The Medicines Company.